scispace - formally typeset
M

Maria Letizia Barreca

Researcher at University of Perugia

Publications -  124
Citations -  3537

Maria Letizia Barreca is an academic researcher from University of Perugia. The author has contributed to research in topics: Integrase & Pharmacophore. The author has an hindex of 34, co-authored 115 publications receiving 3156 citations. Previous affiliations of Maria Letizia Barreca include University of Messina & Katholieke Universiteit Leuven.

Papers
More filters
Journal ArticleDOI

5-arylidene-2-imino-4-thiazolidinones : Design and synthesis of novel anti-inflammatory agents

Rosaria Ottanà, +10 more
- 01 Jul 2005 - 
TL;DR: Five derivatives of 5-arylidene-2-imino-4-thiazolidinones exhibited significant activity levels in models of acute inflammation such as carrageenan-induced paw and pleurisy edema in rats, and the ability of such a new class of anti-inflammatory agents to inhibit COX isoforms was assessed in murine monocyte/macrophage J774 cell line assay.
Journal ArticleDOI

Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents

Maria Letizia Barreca, +10 more
- 09 Jul 2001 - 
TL;DR: SAR studies evidenced that the nature of the substituents at the 2 and 3 positions of the thiazolidinone nucleus largely influenced the in vitro anti-HIV activity of this new class of potent antiviral agents.
Journal ArticleDOI

Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors.

Maria Letizia Barreca, +8 more
- 06 Oct 2005 - 
TL;DR: Using a training set of diketo-like acid HIV-1 integrase (IN) strand-transfer inhibitors, a 3D pharmacophore model was derived having quantitative predictive ability in terms of activity, which guided the rational design of benzylindoles as new potent IN inhibitors, whose microwave-assisted synthesis and biological evaluation are reported.
Journal ArticleDOI

Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents.

Maria Letizia Barreca, +11 more
- 21 Nov 2002 - 
TL;DR: Starting from 1H,3H-thiazolo[3,4-a]benzimidazoles (TBZs), some derivatives proved to be highly effective in inhibiting HIV-1 replication at nanomolar concentrations with minimal cytotoxicity, thereby acting as nonnucleoside HIV- 1 RT inhibitors (NNRTIs).
Journal ArticleDOI

A 1,8-naphthyridone derivative targets the HIV-1 Tat-mediated transcription and potently inhibits the HIV-1 replication.

Serena Massari, +8 more
- 28 Jan 2010 - 
TL;DR: The naphthyridone 3 (HM13N), described in the present study, is a promising anti-HIV agent due to its ability to inhibit the HIV-1 Tat-mediated transcription and the potent antiviral activity observed in acutely, chronically, and latently infected cells.